Table 3 Distribution of outcomes and progression of diseases between both groups
Outcomes | C3GN (n = 10) | C3 (n = 21) | P value |
|---|---|---|---|
Follow up (days) | 405 (203–1197) | 1822 (1243–3948) | 0.02 |
Remission with immunosuppression (%) | 20 (n = 2) | 33(n = 7) | 0.5 |
Partial remission with immunosuppression (%) | 10 (n = 1) | 10 (n = 2) | 0.9 |
Remission without immunosuppression (%) | Nil | 19 (n = 4) | |
Partial remission without immunosuppression (%) | Nil | Nil | |
Relapse (%) | nil | 5 (n = 1) | 0.5 |
Creatinine doubling (%) | 10 (n = 1) | 19 (n = 4) | 0.2 |
Median Creatinine doubling time (days) | 350 NA | 1107.5 (522–2076) | 0.3 |
Median Creatinine doubling amount (umol/L) | 353** NA | 245 (229–277) | 0.3 |
Latest Creatinine (umol/L) | 125 (110–194) | 110 (88–197) | 0.8 |
Pre-emptive transplant (%) | 0 | 14 (n = 3) | 0.08 |
ESRF (HD/PD) | 10 (n = 1) | 14 (n = 3) | 0.09 |
Death (% at 5 year follow up) a | 30 (n = 3) | 14 (n = 3) | 0.02 |
Loss to follow up (%) | 30 (n = 3) | 10 (n = 2) | 0.1 |